Literature DB >> 11459457

Different strategies for formation of pegylated EGF-conjugated PEI/DNA complexes for targeted gene delivery.

T Blessing1, M Kursa, R Holzhauser, R Kircheis, E Wagner.   

Abstract

With the aim of generating gene delivery systems for tumor targeting, we have synthesized a conjugate consisting of polyethylenimine (PEI) covalently modified with epidermal growth factor (EGF) peptides. Transfection efficiency of the conjugate was evaluated and compared to native PEI in three tumor cell lines: KB epidermoid carcinoma cells, CMT-93 rectum carcinoma cells, and Renca-EGFR renal carcinoma cells. Depending on the tumor cell line, incorporation of EGF resulted in an up to 300-fold increased transfection efficiency. This ligand-mediated enhancement and competition with free EGF strongly suggested uptake of the complexes through the EGF receptor-mediated endocytosis pathway. Shielded particles being crucial for systemic gene delivery, we studied the effect of covalent surface modification of EGF-PEI/DNA complexes with a poly(ethylene glycol) (PEG) derivative. An alternative way for the formation of PEGylated EGF-containing complexes was also evaluated where EGF was projected away from PEI/DNA core complexes through a PEG linker. Both strategies led to shielded particles still able to efficiently transfect tumor cells in a receptor-dependent fashion. These PEGylated EGF-containing complexes were 10- to 100-fold more efficient than PEGylated complexes without EGF.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11459457     DOI: 10.1021/bc0001488

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  39 in total

1.  Structural and functional consequences of poly(ethylene glycol) inclusion on DNA condensation for gene delivery.

Authors:  Peter G Millili; Joshua A Selekman; Kory M Blocker; David A Johnson; Ulhas P Naik; Millicent O Sullivan
Journal:  Microsc Res Tech       Date:  2010-09       Impact factor: 2.769

Review 2.  Design of modular non-viral gene therapy vectors.

Authors:  Laura De Laporte; Jennifer Cruz Rea; Lonnie D Shea
Journal:  Biomaterials       Date:  2005-10-21       Impact factor: 12.479

3.  Engineering clustered ligand binding into nonviral vectors: alphavbeta3 targeting as an example.

Authors:  Quinn K T Ng; Marie K Sutton; Pan Soonsawad; Li Xing; Holland Cheng; Tatiana Segura
Journal:  Mol Ther       Date:  2009-02-24       Impact factor: 11.454

4.  Microarray analysis of gene expression profiles in cells transfected with nonviral vectors.

Authors:  Sarah A Plautz; Gina Boanca; Jean-Jack M Riethoven; Angela K Pannier
Journal:  Mol Ther       Date:  2011-08-09       Impact factor: 11.454

Review 5.  Targeted polymeric nanoparticles for cancer gene therapy.

Authors:  Jayoung Kim; David R Wilson; Camila G Zamboni; Jordan J Green
Journal:  J Drug Target       Date:  2015-06-10       Impact factor: 5.121

6.  Network analysis of endogenous gene expression profiles after polyethyleneimine-mediated DNA delivery.

Authors:  Timothy M Martin; Sarah A Plautz; Angela K Pannier
Journal:  J Gene Med       Date:  2013 Mar-Apr       Impact factor: 4.565

7.  Metabolically stabilized long-circulating PEGylated polyacridine peptide polyplexes mediate hydrodynamically stimulated gene expression in liver.

Authors:  C A Fernandez; N J Baumhover; J T Duskey; S Khargharia; K Kizzire; M D Ericson; K G Rice
Journal:  Gene Ther       Date:  2010-08-19       Impact factor: 5.250

8.  Enhancement of transfection efficiency through rapid and noncovalent post-PEGylation of poly(dimethylaminoethyl methacrylate)/DNA complexes.

Authors:  Sabine Pirotton; Caroline Muller; Nadège Pantoustier; François Botteman; Sébastien Collinet; Christian Grandfils; Guy Dandrifosse; Philippe Degée; Philippe Dubois; Martine Raes
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

9.  Polyethylenimine-mediated gene delivery to the lung and therapeutic applications.

Authors:  Sante Di Gioia; Massimo Conese
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

10.  Targeting the EGF receptor for ovarian cancer therapy.

Authors:  Reema Zeineldin; Carolyn Y Muller; M Sharon Stack; Laurie G Hudson
Journal:  J Oncol       Date:  2009-12-28       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.